Literature DB >> 23780916

Treatment outcomes and feasibility of partial neck irradiation for patients with nasopharyngeal carcinoma with only retropharyngeal lymph node metastasis after intensity-modulated radiotherapy.

Mo Chen1, Ling-Long Tang, Ying Sun, Yan-Ping Mao, Wen-Fei Li, Rui Guo, Li-Zhi Liu, Li Li, Ai-Hua Lin, Jun Ma.   

Abstract

BACKGROUND: The purpose of this study was to summarize the treatment outcomes and evaluate the feasibility of partial neck irradiation in patients with nasopharyngeal carcinoma (NPC) with only retropharyngeal lymph nodes (RLNs) metastasis.
METHODS: Between January 2003 and December 2007, 54 patients with NPC who received partial neck irradiation to levels II, III, and VA and 100 patients who received whole neck irradiation were reviewed.
RESULTS: The 5-year disease free survival (DFS), disease metastasis-free survival, (DMFS) local relapse-free survival (LRFS), and regional relapse-free survival (RRFS) rates were 81.8%, 87.7%, 94.8%, and 98.1%, respectively. The 5-year RRFS and DFS rates for the partial neck irradiation group and whole neck irradiation group were 98.1% versus 98.0% (p = .882), 87.0% vs 77.0% (p = .117), respectively. Partial neck irradiation was not considered a significant prognostic factor for any endpoint in univariate and multivariate analyses.
CONCLUSION: Partial irradiation of neck levels II, III, and VA might be acceptable for patients with NPC with only RLN metastasis.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  intensity-modulated radiotherapy; nasopharyngeal carcinoma; partial neck irradiation; recurrence; retropharyngeal lymph node

Mesh:

Year:  2013        PMID: 23780916     DOI: 10.1002/hed.23314

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  [Is elective irradiation of lymph node levels IV and Vb necessary in nasopharyngeal carcinoma?]

Authors:  Sabine Semrau; Marlen Haderlein
Journal:  Strahlenther Onkol       Date:  2022-08-11       Impact factor: 4.033

2.  RNAi-mediated knockdown of PFK1 decreases the invasive capability and metastasis of nasopharyngeal carcinoma cell line, CNE-2.

Authors:  Shuo Li; Peng He; Zhiwei Wang; Meng Liang; Wei Liao; Yili Huang; Mengshi Chi; Fei Liu; Nan Zen; Rongfei Su; Shulin Chen; Zhigang Liu; Haiyu Hong
Journal:  Cell Cycle       Date:  2021-01-06       Impact factor: 4.534

3.  The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma.

Authors:  Li Lin; Ji-Jin Yao; Guan-Qun Zhou; Rui Guo; Fan Zhang; Yuan Zhang; Lin Xu; Lu-Lu Zhang; Ai-Hua Lin; Jun Ma; Ying Sun
Journal:  Oncotarget       Date:  2016-04-12

4.  Contralateral Lower Neck Sparing Radiotherapy in Stage N1 Nasopharyngeal Carcinoma: Long-Term Survival Outcomes and Late Toxicities.

Authors:  Zhuang Sun; Jingyun Wang; Runda Huang; Xiaohui Wang; Chunyan Chen; Meiling Deng; Chong Zhao; Hanyu Wang; Fei Han
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

5.  Lower-Neck Sparing Using Proton Therapy in Patients with Uninvolved Neck Nasopharyngeal Carcinoma: Is It Safe?

Authors:  Francesca De Felice; Alessandro Vai; Anna Maria Camarda; Nicola Alessandro Iacovelli; Ester Orlandi
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

6.  Feasibility of ipsilateral lower neck sparing irradiation for unilateral or bilateral neck node-negative nasopharyngeal carcinoma: systemic review and meta-analysis of 2, 521 patients.

Authors:  Cheng-Long Huang; Cheng Xu; Yuan Zhang; Guan-Qun Zhou; Yan-Ping Mao; Qing Liu; Ying Sun; Jun Ma; Ling-Long Tang
Journal:  Radiat Oncol       Date:  2018-08-06       Impact factor: 3.481

7.  The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.

Authors:  Ling-Long Tang; Yu-Pei Chen; Chuan-Ben Chen; Ming-Yuan Chen; Nian-Yong Chen; Xiao-Zhong Chen; Xiao-Jing Du; Wen-Feng Fang; Mei Feng; Jin Gao; Fei Han; Xia He; Chao-Su Hu; De-Sheng Hu; Guang-Yuan Hu; Hao Jiang; Wei Jiang; Feng Jin; Jin-Yi Lang; Jin-Gao Li; Shao-Jun Lin; Xu Liu; Qiu-Fang Liu; Lin Ma; Hai-Qiang Mai; Ji-Yong Qin; Liang-Fang Shen; Ying Sun; Pei-Guo Wang; Ren-Sheng Wang; Ruo-Zheng Wang; Xiao-Shen Wang; Ying Wang; Hui Wu; Yun-Fei Xia; Shao-Wen Xiao; Kun-Yu Yang; Jun-Lin Yi; Xiao-Dong Zhu; Jun Ma
Journal:  Cancer Commun (Lond)       Date:  2021-10-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.